Francois Martelet, M.D.

Chief Executive Officer

Education: Doctorate in Medicine, Dijon University of Medicine. Master’s Degree in Business, Pharmaceutical Marketing, Burgundy Business School. Advanced Management Program, INSEAD. Executive education finance & management programs, Harvard Business School.

Francois Martelet’s career in the global pharmaceutical and biotech industry spans more than 30 years and he has more than 20 years of experience as senior level executive.

Francois Martelet has worked and held global leadership positions in large pharmaceutical companies including F. Hoffmann la Roche Ltd., Eli Lilly & Co., Novartis Pharma AG and Merck & Co., Inc. and has also been CEO and chairman of a number of biotech companies in Europe and in the US, including Topotarget A/S. Prior to joining Scandion Oncology A/S, Francois Martelet was CEO of a biotech company Vivesto AB based in Sweden.

Ongoing assignments: Board member of Novigenix SA.

Year of commencement of the position: 2023.

Independence: Independent in relation to both the Company and larger shareholders.

Scandion Oncology shares and warrants:
11.184 shares and 600.000 warrants.

Varia: Francois is recipient of the Legion d’Honneur as knight, which is the highest decoration in France.